A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE

Journal of Neural Transmission

Volumn 120, Issue 6, 2013, Pages 911-918

  Esteban, Gerard ^a   Bolea, Irene ^a   Sun, Ping ^a   Solé, Montse ^a   Samadi, Abdelouahid ^b   Marco Contelles, José ^b   Unzeta, Mercedes ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INSTITUTO DE QUÍMICA ORGÁNICA GENERAL   (Spain)

Author keywords

Acetylcholinesterase; Butyrylcholinesterase; Hydrazide; Hydrazine; Monoamine oxidase; Vascular adhesion protein 1

Indexed keywords

3 (3 HYDRAZINYLPROPYL) 1H INDOLE; ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CLORGYLINE; DONEPEZIL; HYDRAZIDE DERIVATIVE; HYDRAZINE DERIVATIVE; JL 317; JL 34; JL 40; JL 411; JL 418; JL 432; JL 71; JL 72; JL 87; MONOAMINE OXIDASE A INHIBITOR; MONOAMINE OXIDASE B INHIBITOR; PHENELZINE; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CEREBROVASCULAR DISEASE; CHOLINESTERASE INHIBITION; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONINERGIC TRANSMISSION; STRUCTURE ACTIVITY RELATION;

ACETYLCHOLINESTERASE; AMINE OXIDASE (COPPER-CONTAINING); ANIMALS; BUTYRYLCHOLINESTERASE; CELL ADHESION MOLECULES; CELL LINE, TRANSFORMED; CEREBROVASCULAR DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYDRAZINES; INDOLES; KINETICS; LEUKOCYTES; MONOAMINE OXIDASE; RATS; TIME FACTORS; TRANSFECTION;

EID: 84878717554     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-012-0949-x     Document Type: Article

References (30)

1. Alemany A, Bernabé M, Elorriaga C, Fernández-Alvarez E, Lora-Tamayo M, Nieto O (1966) Potential psychotropic agents. I. Synthesis of 1-(2-indolylcarbonyl)-2-alkylhydrazines, 1-(3-indolylcarbonyl)-2-alkylhydrazines and 1-(3-indolylacetyl)-2-alkylhydrazines, and measurement, in vitro, of their monoamine oxidase inhibitory activity. Bull Soc Chim Fr 8:2486-2497
2. Alemany A, Fernández-Álvarez E, Hernández- Sánchez M (1975) Enzyme inhibitors. X. Preparation and in vitro study of N2-substituted 2-(N-methylindolyl) and 2-(N- benzylindolyl) carbohydrazides as monoamineoxidase inhibitors. An Quím 71:406-411
3. Bernabé M, Fernández-Álvarez E, Lora-Tamayo M, Nieto O (1971) Potential psychotropic drugs. V. Monoamine oxidase inhibitors. Preparation and study of some indolyl-3 alkyl-hydrazines. Bull Soc Chim Fr 5:1882-1887
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
5. Castro A, Martínez A (2006) Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors. Curr Pharm Des 12:4377-4387
6. Davies P, Maloney AJ (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2:1403
7. Deane R, Wu Z, Sagare A, Davis J, Du YS, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43:333-344
8. Ellman GL, Courtney KD, Andres V Jr, Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88-95
9. Ferrer I, Lizcano JM, Hernández M, Unzeta M (2002) Overexpression of semicarbazide sensitive amine oxidase in the cerebral blood vessels in patients with Alzheimer's disease and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. Neurosci Lett 321:21-24
10. Fowler CJ, Tipton KF (1981) Concentration dependence of the oxidation of tyramine by the two forms of rat liver mitochondrial monoamine oxidase. Biochem Pharmacol 30:3329-3332
11. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, Ramirez MJ (2005) Cholinergic-serotoninergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 43:442-449
12. Geula C, Mesulam MM (1999) Cholinergic systems in Alzheimer's disease. In: Terry RD, Katzman R, Bick K, Sisodia SS (eds) Alzheimer disease, 2nd edn. Lippincott Williams & Wilkins, Philadelphia, PA, pp 69-292
13. Goedert M, Spillantini MG (2006) A century of Alzheimer's disease. Science 314:777-781
14. Gomez N, Unzeta M, Tipton KF, Anderson MC, O'Carroll AM (1986) Determination of monoamine oxidase concentrations in rat liver by inhibitor binding. Biochem Pharmacol 35:4467-4472
15. Hernandez-Guillamon M, Garcia-Bonilla L, Solé M, Sosti V, Parés M, Campos M, Ortega-Aznar A, Domínguez C, Rubiera M, Ribó M, Quintana M, Molina CA, Alvarez-Sabín J, Rosell A, Unzeta M, Montaner J (2010) Plasma VAP-1/SSAO activity predicts intracranial hemorrhages and adverse neurological outcome after tissue plasminogen activator treatment in stroke. Stroke 41:1528-1535
16. Hernandez-Guillamon M, Solé M, Delgado P, García-Bonilla L, Giralt D, Boada C, Penalba A, García S, Flores A, Ribó M, Alvarez-Sabin J, Ortega-Aznar A, Unzeta M, Montaner J (2012) VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke. Cerebrovasc Dis 33:55-63
17. Jalkanen S, Salmi M (2008) VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol 28:18-26
18. Johnston JP (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochem Pharmacol 17:1285-1297
19. Koskinen K, Vainio PJ, Smith DJ, Pihlavisto M, Ylä-Herttuala S, Jalkanen S, Salmi M (2004) Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1). Blood 103:3388-3395
20. Lizcano JM, Fernández de Arriba A, Tipton KF, Unzeta M (1996) Inhibition of bovine lung semicarbazide-sensitive amine oxidase (SSAO) by some hydrazine derivatives. Biochem Pharmacol 52:187-195
21. Monge A, Palop JA, Goni T, Martinez A, Fernandez-Alvarez E (1985) About the synthesis of (1,2) diazepinoindole derivatives from ethyl 2-(1-methylindole)acetate, 2-indole- and 3-indoleacetohydrazones. J Heterocyclic Chem 22:1445-1451
22. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63
23. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE (1977) Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34:247-265
24. Salmi M, Kalimo K, Jalkanen S (1993) Induction and function of vascular adhesion protein-1 at sites of inflammation. J Exp Med 178:2255-2260
25. Solé M, Unzeta M (2011) Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases. Biol Cell 103:543-557
26. Song MS, Baker GB, Dursun SM, Todd KG (2010) The antidepressant phenelzine protects neurons and astrocytes against formaldehyde-induced toxicity. J Neurochem 114:1405-1413
27. Terry AV Jr, Buccafusco JJ, Wilson C (2008) Cognitive dysfunction in neuropsychiatric disorders: selected serotonin receptor subtypes as therapeutic targets. Behav Brain Res 195:30-38
28. Vinters HV, Pardridge WM, Secor DL, Ishii N (1988) Immunohistochemical study of cerebral amyloid angiopathy. II. Enhancement of immunostaining using formic acid pretreatment of tissue sections. Am J Pathol 133:150-162
29. Wood PL, Khan MA, Moskal JR, Todd KG, Tanay VA, Baker G (2006) Aldehyde load in ischemia-reperfusion brain injury: neuroprotection by neutralization of recative aldehydes with phenelzine. Brain Res 1122:184-190
30. Zlokovic BV (2005) Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 28:202-208